An Australian government research funding programme is helping commercialise a mobile app for screening cerebral palsy in infants at home. Developed at the University of Melbourne, the Baby Moves VIEW ...

Lauren Silva, a freelance writer in New York City, believes in feeling good in your body and making that experience accessible to everyone across generations. The proof is in her ever-piling browser ...

Today, Cerebral launched its mobile app on both iOS and Android platforms. The Cerebral app now allows Cerebral members across the country to receive their care wherever they are. Since launching in ...

Telepsychiatry app Cerebral has grown explosively during the pandemic, but 27 former employees said the company could be fueling a new addiction crisis, according to a March 11 Bloomberg report.

North Texas children who have cerebral palsy are reaching milestones once never thought possible, and their families credit the power of a new medical-based app that is changing lives. Cerebral palsy ...

With SoftBank’s second vision fund as a backer, mental health startup Cerebral recently closed a $300 million funding round. The startup has raised a total of $462 million to date, giving it a $4.8 ...

In a follow-up to a CBS News investigation of online mental health app Cerebral, CBS News’ Anna Werner takes a look at new concerns about how the platform, which offers therapy and prescriptions, ...

Broadcast Wed 6 Sep 2017 at 10:22pm Wednesday 6 Sep 2017 at 10:22pm Wed 6 Sep 2017 at 10:22pm Space to play or pause, M to mute, left and right arrows to seek, up and down arrows for volume. One in ...

- Results Provide First Demonstration of Gene Silencing by RNAi Therapeutics in the Human Brain Using Alnylam's Proprietary C16 Platform - Twenty patients have been enrolled in three single-dose ...

CAMBRIDGE, Mass. & TARRYTOWN, N.Y.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced today positive interim results from the ...

– First Patient Dosed in Multiple-dose Part B Portion of Study, with the Study Proceeding in Canada, UK, and the Netherlands – CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq ...